{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T12:24:23Z","timestamp":1780489463460,"version":"3.54.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T00:00:00Z","timestamp":1773446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T00:00:00Z","timestamp":1773446400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurogenetics"],"DOI":"10.1007\/s10048-026-00881-8","type":"journal-article","created":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T08:33:13Z","timestamp":1773477193000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Targeting ABC transporters in glioma: farnesiferols as potent agents against chemotherapy resistance"],"prefix":"10.1007","volume":"27","author":[{"given":"Hamidreza","family":"Jamali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad Vosough","family":"Ghanbari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh B.","family":"Rassouli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,14]]},"reference":[{"issue":"3","key":"881_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74(3):229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"key":"881_CR2","doi-asserted-by":"publisher","first-page":"937556","DOI":"10.3389\/fsurg.2022.937556","volume":"9","author":"Z Yan","year":"2022","unstructured":"Yan Z, Wang J, Dong Q, Zhu L, Lin W, Jiang X (2022) Predictors of tumor progression of low-grade glioma in adult patients within 5 years follow-up after surgery. Front Surg 9:937556. https:\/\/doi.org\/10.3389\/fsurg.2022.937556","journal-title":"Front Surg"},{"issue":"1","key":"881_CR3","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s40478-020-00902-z","volume":"8","author":"S Ryall","year":"2020","unstructured":"Ryall S, Tabori U, Hawkins C (2020) Pediatric low-grade glioma in the era of molecular diagnostics. Acta Neuropathol Commun 8(1):30. https:\/\/doi.org\/10.1186\/s40478-020-00902-z","journal-title":"Acta Neuropathol Commun"},{"issue":"1","key":"881_CR4","doi-asserted-by":"publisher","first-page":"E6","DOI":"10.3171\/2014.10.FOCUS12367","volume":"38","author":"EB Claus","year":"2015","unstructured":"Claus EB, Walsh KM, Wiencke JK, Molinaro AM, Wiemels JL, Schildkraut JM, Bondy ML, Berger M, Jenkins R, Wrensch M (2015) Survival and low-grade glioma: the emergence of genetic information. Neurosurg Focus 38(1):E6. https:\/\/doi.org\/10.3171\/2014.10.FOCUS12367","journal-title":"Neurosurg Focus"},{"key":"881_CR5","doi-asserted-by":"publisher","first-page":"963","DOI":"10.3389\/fonc.2019.00963","volume":"9","author":"OG Taylor","year":"2019","unstructured":"Taylor OG, Brzozowski JS, Skelding KA (2019) Glioblastoma multiforme: an overview of emerging therapeutic targets. Front Oncol 9:963. https:\/\/doi.org\/10.3389\/fonc.2019.00963","journal-title":"Front Oncol"},{"key":"881_CR6","doi-asserted-by":"publisher","first-page":"200","DOI":"10.3389\/fphar.2019.00200","volume":"10","author":"E Ladomersky","year":"2019","unstructured":"Ladomersky E, Scholtens DM, Kocherginsky M, Hibler EA, Bartom ET, Otto-Meyer S, Zhai L, Lauing KL, Choi J, Sosman JA, Wu JD, Zhang B, Lukas RV, Wainwright DA (2019) The coincidence between increasing age, immunosuppression, and the incidence of patients with glioblastoma. Front Pharmacol 10:200. https:\/\/doi.org\/10.3389\/fphar.2019.00200","journal-title":"Front Pharmacol"},{"issue":"1","key":"881_CR7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.22034\/APJCP.2017.18.1.3","volume":"18","author":"F Hanif","year":"2017","unstructured":"Hanif F, Muzaffar K, Perveen K, Malhi SM, Simjee Sh U (2017) Glioblastoma multiforme: a review of its epidemiology and pathogenesis through clinical presentation and treatment. Asian Pac J Cancer Prev 18(1):3\u20139. https:\/\/doi.org\/10.22034\/APJCP.2017.18.1.3","journal-title":"Asian Pac J Cancer Prev"},{"key":"881_CR8","doi-asserted-by":"publisher","first-page":"123476","DOI":"10.1016\/j.wneu.2024.11.059","volume":"194","author":"Z Alirezaei","year":"2025","unstructured":"Alirezaei Z, Amouheidari A, Basirian Jahromi R, Seyyedhosseini S, Hamidi A (2025) Survival analysis of glioblastoma: a scientometric perspective. World Neurosurg 194:123476. https:\/\/doi.org\/10.1016\/j.wneu.2024.11.059","journal-title":"World Neurosurg"},{"key":"881_CR9","doi-asserted-by":"publisher","unstructured":"Zhou YS, Wang W, Chen N, Wang LC, Huang JB (2022) Research progress of anti-glioma chemotherapeutic drugs (Review). Oncol Rep 47(5). https:\/\/doi.org\/10.3892\/or.2022.8312","DOI":"10.3892\/or.2022.8312"},{"issue":"4","key":"881_CR10","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1200\/OP.22.00476","volume":"19","author":"R Kotecha","year":"2023","unstructured":"Kotecha R, Odia Y, Khosla AA, Ahluwalia MS (2023) Key clinical principles in the management of glioblastoma. JCO Oncol Pract 19(4):180\u2013189. https:\/\/doi.org\/10.1200\/OP.22.00476","journal-title":"JCO Oncol Pract"},{"issue":"11","key":"881_CR11","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1007\/s40263-020-00766-w","volume":"34","author":"R Haumann","year":"2020","unstructured":"Haumann R, Videira JC, Kaspers GJL, van Vuurden DG, Hulleman E (2020) Overview of current drug delivery methods across the blood-brain barrier for the treatment of primary brain tumors. CNS Drugs 34(11):1121\u20131131. https:\/\/doi.org\/10.1007\/s40263-020-00766-w","journal-title":"CNS Drugs"},{"key":"881_CR12","doi-asserted-by":"publisher","first-page":"105780","DOI":"10.1016\/j.phrs.2021.105780","volume":"171","author":"W Wu","year":"2021","unstructured":"Wu W, Klockow JL, Zhang M, Lafortune F, Chang E, Jin L, Wu Y, Daldrup-Link HE (2021) Glioblastoma multiforme (GBM): an overview of current therapies and mechanisms of resistance. Pharmacol Res 171:105780. https:\/\/doi.org\/10.1016\/j.phrs.2021.105780","journal-title":"Pharmacol Res"},{"issue":"7","key":"881_CR13","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/s41568-018-0005-8","volume":"18","author":"RW Robey","year":"2018","unstructured":"Robey RW, Pluchino KM, Hall MD, Fojo AT, Bates SE, Gottesman MM (2018) Revisiting the role of ABC transporters in multidrug-resistant cancer. Nat Rev Cancer 18(7):452\u2013464. https:\/\/doi.org\/10.1038\/s41568-018-0005-8","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"881_CR14","first-page":"827","volume":"336","author":"S Agarwal","year":"2011","unstructured":"Agarwal S, Sane R, Ohlfest JR, Elmquist WF (2011) The role of the blood-brain barrier and the efflux transporters P-glycoprotein and breast cancer resistance protein in the distribution of a novel tyrosine kinase inhibitor in brain. J Pharmacol Exp Ther 336(2):827\u2013835","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"881_CR15","doi-asserted-by":"publisher","first-page":"102","DOI":"10.3390\/ph18010102","volume":"18","author":"BWS Phon","year":"2025","unstructured":"Phon BWS, Chelliah SS, Osman DE, Bhuvanendran S, Radhakrishnan AK, Kamarudin MNA (2025) Revisiting ABC transporters and their clinical significance in glioblastoma. Pharmaceuticals (Basel) 18(1):102. https:\/\/doi.org\/10.3390\/ph18010102","journal-title":"Pharmaceuticals (Basel)"},{"key":"881_CR16","doi-asserted-by":"publisher","unstructured":"Majchrzak-Celi\u0144ska A, Sidhu A, Miechowicz I, Nowak W, Barciszewska AM (2022) ABCB1 is frequently methylated in higher-grade gliomas and May serve as a diagnostic biomarker of more aggressive tumors. J Clin Med 11(19). https:\/\/doi.org\/10.3390\/jcm11195655","DOI":"10.3390\/jcm11195655"},{"issue":"3","key":"881_CR17","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s11060-018-2819-3","volume":"138","author":"A Dr\u00e9an","year":"2018","unstructured":"Dr\u00e9an A, Rosenberg S, Lejeune FX, Goli L, Nadaradjane AA, Guehennec J, Schmitt C, Verreault M, Bielle F, Mokhtari K, Sanson M, Carpentier A, Delattre JY, Idbaih A (2018) ATP binding cassette (ABC) transporters: expression and clinical value in glioblastoma. J Neurooncol 138(3):479\u2013486. https:\/\/doi.org\/10.1007\/s11060-018-2819-3","journal-title":"J Neurooncol"},{"key":"881_CR18","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1186\/1471-2407-13-617","volume":"13","author":"MC Oberstadt","year":"2013","unstructured":"Oberstadt MC, Bien-M\u00f6ller S, Weitmann K, Herzog S, Hentschel K, Rimmbach C, Vogelgesang S, Balz E, Fink M, Michael H, Zeden JP, Bruckm\u00fcller H, Werk AN, Cascorbi I, Hoffmann W, Rosskopf D, Schroeder HW, Kroemer HK (2013) Epigenetic modulation of the drug resistance genes MGMT, ABCB1 and ABCG2 in glioblastoma multiforme. BMC Cancer 13:617. https:\/\/doi.org\/10.1186\/1471-2407-13-617","journal-title":"BMC Cancer"},{"issue":"3","key":"881_CR19","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s11060-022-04179-1","volume":"160","author":"LO Roy","year":"2022","unstructured":"Roy LO, Lemelin M, Blanchette M, Poirier MB, Aldakhil S, Fortin D (2022) Expression of ABCB1, ABCC1 and 3 and ABCG2 in glioblastoma and their relevance in relation to clinical survival surrogates. J Neurooncol 160(3):601\u2013609. https:\/\/doi.org\/10.1007\/s11060-022-04179-1","journal-title":"J Neurooncol"},{"issue":"8","key":"881_CR20","first-page":"3892","volume":"12","author":"Z Chen","year":"2022","unstructured":"Chen Z, Zhang Y, Chen Y, Lin W, Zhang Y, Cai G, Sun X, Zheng K, He J, Ai T, Wang J, Zhao L, Ke Y (2022) Prrx1 promotes resistance to Temozolomide by upregulating ABCC1 and inducing vasculogenic mimicry in glioma. Am J Cancer Res 12(8):3892\u20133912 PMID: 36119823","journal-title":"Am J Cancer Res"},{"key":"881_CR21","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.tiv.2018.07.001","volume":"52","author":"F Hanif","year":"2018","unstructured":"Hanif F, Perveen K, Malhi SM, Jawed H, Simjee SU (2018) Verapamil potentiates anti-glioblastoma efficacy of Temozolomide by modulating apoptotic signaling. Toxicol In Vitro 52:306\u2013313. https:\/\/doi.org\/10.1016\/j.tiv.2018.07.001","journal-title":"Toxicol In Vitro"},{"issue":"2","key":"881_CR22","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/bjc.1995.348","volume":"72","author":"T Abe","year":"1995","unstructured":"Abe T, Koike K, Ohga T, Kubo T, Wada M, Kohno K, Mori T, Hidaka K, Kuwano M (1995) Chemosensitisation of spontaneous multidrug resistance by a 1,4-dihydropyridine analogue and verapamil in human glioma cell lines overexpressing MRP or MDR1. Br J Cancer 72(2):418\u2013423. https:\/\/doi.org\/10.1038\/bjc.1995.348","journal-title":"Br J Cancer"},{"issue":"2","key":"881_CR23","doi-asserted-by":"publisher","first-page":"93","DOI":"10.2174\/1874467210801020093","volume":"1","author":"CP Wu","year":"2008","unstructured":"Wu CP, Calcagno AM, Ambudkar SV (2008) Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies. Curr Mol Pharmacol 1(2):93\u2013105. https:\/\/doi.org\/10.2174\/1874467210801020093","journal-title":"Curr Mol Pharmacol"},{"key":"881_CR24","first-page":"795","volume":"69","author":"AB Benson","year":"1985","unstructured":"Benson AB, Trump DL, Koeller JM, Egorin MI, Olman EA, Witte RS, Davis TE, Tormey DC (1985) Phase I study of vinblastine and verapamil given by concurrent Iv infusion. Cancer Treat Rep 69:795\u2013799 PMID: 4016789","journal-title":"Cancer Treat Rep"},{"issue":"2","key":"881_CR25","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1158\/1535-7163.MCT-09-0775","volume":"9","author":"JH Lee","year":"2010","unstructured":"Lee JH, Choi S, Lee Y, Lee HJ, Kim KH, Ahn KS, Bae H, Lee HJ, Lee EO, Ahn KS, Ryu SY, L\u00fc J, Kim SH (2010) Herbal compound Farnesiferol C exerts antiangiogenic and antitumor activity and targets multiple aspects of VEGFR1 (Flt1) or VEGFR2 (Flk1) signaling cascades. Mol Cancer Ther 9(2):389\u2013399. https:\/\/doi.org\/10.1158\/1535-7163.MCT-09-0775","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"881_CR26","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/2008-2231-21-39","volume":"21","author":"SM Valiahdi","year":"2013","unstructured":"Valiahdi SM, Iranshahi M, Sahebkar A (2013) Cytotoxic activities of phytochemicals from Ferula species. DARU J Pharm Sci 21(1):39. https:\/\/doi.org\/10.1186\/2008-2231-21-39","journal-title":"DARU J Pharm Sci"},{"issue":"13","key":"881_CR27","doi-asserted-by":"publisher","first-page":"5325","DOI":"10.7314\/apjcp.2015.16.13.5325","volume":"16","author":"Z Aas","year":"2015","unstructured":"Aas Z, Babaei E, Hosseinpour Feizi MA, Dehghan G (2015) Anti-proliferative and apoptotic effects of dendrosomal Farnesiferol C on gastric cancer cells. Asian Pac J Cancer Prev 16(13):5325\u20135329. https:\/\/doi.org\/10.7314\/apjcp.2015.16.13.5325","journal-title":"Asian Pac J Cancer Prev"},{"key":"881_CR28","doi-asserted-by":"publisher","first-page":"26844","DOI":"10.1038\/srep26844","volume":"6","author":"JH Jung","year":"2016","unstructured":"Jung JH, Kim MJ, Lee H, Lee J, Kim J, Lee HJ, Shin EA, Kim YH, Kim B, Shim BS, Kim SH (2016) Farnesiferol c induces apoptosis via regulation of L11 and c-Myc with combinational potential with anticancer drugs in non-small-cell lung cancers. Sci Rep 6:26844. https:\/\/doi.org\/10.1038\/srep26844","journal-title":"Sci Rep"},{"issue":"11","key":"881_CR29","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1080\/07391102.2018.1497543","volume":"37","author":"H Tanzadehpanah","year":"2019","unstructured":"Tanzadehpanah H, Mahaki H, Samadi P, Karimi J, Moghadam NH, Salehzadeh S, Dastan D, Saidijam M (2019) Anticancer activity, calf thymus DNA and human serum albumin binding properties of Farnesiferol C from ferula pseudalliacea. J Biomol Struct Dyn 37(11):2789\u20132800. https:\/\/doi.org\/10.1080\/07391102.2018.1497543","journal-title":"J Biomol Struct Dyn"},{"issue":"1","key":"881_CR30","doi-asserted-by":"publisher","first-page":"2565463","DOI":"10.1080\/14756366.2025.2565463","volume":"40","author":"N Moosavinejad","year":"2025","unstructured":"Moosavinejad N, Nasiri Sarvi Z, Gholamhosseinian H, Iranshahi M, Rassouli FB (2025) Farnesiferol C enhances the effects of chemotherapy and ionising radiation in human melanoma cells via targeting topoisomerase II alpha. J Enzyme Inhib Med Chem 40(1):2565463. https:\/\/doi.org\/10.1080\/14756366.2025.2565463","journal-title":"J Enzyme Inhib Med Chem"},{"issue":"14","key":"881_CR31","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1055\/s-0030-1270987","volume":"77","author":"MY Hanafi-Bojd","year":"2011","unstructured":"Hanafi-Bojd MY, Iranshahi M, Mosaffa F, Tehrani SO, Kalalinia F, Behravan J (2011) Farnesiferol A from ferula persica and Galbanic acid from ferula Szowitsiana inhibit P-glycoprotein-mediated Rhodamine efflux in breast cancer cell lines. Planta Med 77(14):1590\u20131593. https:\/\/doi.org\/10.1055\/s-0030-1270987","journal-title":"Planta Med"},{"issue":"11","key":"881_CR32","doi-asserted-by":"publisher","first-page":"e2220012120","DOI":"10.1073\/pnas.2220012120","volume":"120","author":"HL Pietz","year":"2023","unstructured":"Pietz HL, Abbas A, Johnson ZL, Oldham ML, Suga H, Chen J (2023) A macrocyclic peptide inhibitor traps MRP1 in a catalytically incompetent conformation. Proc Natl Acad Sci U S A 120(11):e2220012120. https:\/\/doi.org\/10.1073\/pnas.2220012120","journal-title":"Proc Natl Acad Sci U S A"},{"key":"881_CR33","doi-asserted-by":"publisher","first-page":"149855","DOI":"10.1016\/j.bbrc.2024.149855","volume":"709","author":"N Hamaguchi-Suzuki","year":"2024","unstructured":"Hamaguchi-Suzuki N, Adachi N, Moriya T, Yasuda S, Kawasaki M, Suzuki K, Ogasawara S, Anzai N, Senda T, Murata T (2024) Cryo-EM structure of P-glycoprotein bound to triple elacridar inhibitor molecules. Biochem Biophys Res Commun 709:149855. https:\/\/doi.org\/10.1016\/j.bbrc.2024.149855","journal-title":"Biochem Biophys Res Commun"},{"key":"881_CR34","doi-asserted-by":"publisher","first-page":"1380371","DOI":"10.3389\/fphar.2024.1380371","volume":"15","author":"A Gupta","year":"2024","unstructured":"Gupta A, Singh MS, Singh B (2024) Deciphering the functional role of clinical mutations in ABCB1, ABCC1, and ABCG2 ABC transporters in cancer. Front Pharmacol 15:1380371. https:\/\/doi.org\/10.3389\/fphar.2024.1380371","journal-title":"Front Pharmacol"},{"issue":"11","key":"881_CR35","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/s41568-023-00612-3","volume":"23","author":"A Sajid","year":"2023","unstructured":"Sajid A, Rahman H, Ambudkar SV (2023) Advances in the structure, mechanism and targeting of chemoresistance-linked ABC transporters. Nat Rev Cancer 23(11):762\u2013779. https:\/\/doi.org\/10.1038\/s41568-023-00612-3","journal-title":"Nat Rev Cancer"},{"issue":"10","key":"881_CR36","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1056\/NEJMoa2304194","volume":"389","author":"IK Mellinghoff","year":"2023","unstructured":"Mellinghoff IK, Penas-Prado M, Peters KB et al (2023) Vorasidenib in IDH1- or IDH2-mutant low-grade glioma. N Engl J Med 389(10):889\u2013900. https:\/\/doi.org\/10.1056\/NEJMoa2304194","journal-title":"N Engl J Med"},{"issue":"1","key":"881_CR37","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1080\/10286020.2017.1379997","volume":"20","author":"J Kasaian","year":"2018","unstructured":"Kasaian J, Mohammadi A (2018) Biological activities of farnesiferol C: a review. J Asian Nat Prod Res 20(1):27\u201335. https:\/\/doi.org\/10.1080\/10286020.2017.1379997","journal-title":"J Asian Nat Prod Res"},{"issue":"2","key":"881_CR38","doi-asserted-by":"publisher","first-page":"28","DOI":"10.4331\/wjbc.v14.i2.28","volume":"14","author":"MAG Sirizi","year":"2023","unstructured":"Sirizi MAG, Alizadeh Ghalenoei J, Allahtavakoli M, Forouzanfar H, Bagheri SM (2023) Anticancer potential of ferula assa-foetida and its constituents, a powerful plant for cancer therapy. World J Biol Chem 14(2):28\u201339. https:\/\/doi.org\/10.4331\/wjbc.v14.i2.28","journal-title":"World J Biol Chem"},{"key":"881_CR39","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.toxrep.2017.07.010","volume":"4","author":"D Hasanzadeh","year":"2017","unstructured":"Hasanzadeh D, Mahdavi M, Dehghan G, Charoudeh HN (2017) Farnesiferol C induces cell cycle arrest and apoptosis mediated by oxidative stress in MCF-7 cell line. Toxicol Rep 4:420\u2013426. https:\/\/doi.org\/10.1016\/j.toxrep.2017.07.010","journal-title":"Toxicol Rep"},{"issue":"5","key":"881_CR40","first-page":"446","volume":"9","author":"M Iranshahy","year":"2019","unstructured":"Iranshahy M, Farhadi F, Paknejad B, Zareian P, Iranshahi M, Karami M, Abtahi SR (2019) Gummosin, a sesquiterpene coumarin from Ferula assa-foetida is preferentially cytotoxic to human breast and prostate cancer cell lines. Avicenna J Phytomed 9(5):446\u2013453","journal-title":"Avicenna J Phytomed"},{"key":"881_CR41","doi-asserted-by":"publisher","DOI":"10.3390\/ph15091070","author":"A Alafnan","year":"2022","unstructured":"Alafnan A, Alamri A, Alanazi J, Hussain T (2022) Farnesiferol c exerts antiproliferative effects on hepatocellular carcinoma HepG2 cells by instigating ROS-dependent apoptotic pathway. Pharmaceuticals (Basel). https:\/\/doi.org\/10.3390\/ph15091070","journal-title":"Pharmaceuticals (Basel)"},{"key":"881_CR42","doi-asserted-by":"publisher","unstructured":"Jung JH, Park JE, Sim DY, Im E, Park WY, Lee D, Shim BS, Kim SH (2019) Farnesiferol C induces apoptosis in chronic myelogenous leukemia cells as an Imatinib sensitizer via caspase activation and HDAC (histone deacetylase) inactivation. Int J Mol Sci 20(22). https:\/\/doi.org\/10.3390\/ijms20225535","DOI":"10.3390\/ijms20225535"},{"issue":"1514","key":"881_CR43","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1098\/rstb.2008.0125","volume":"364","author":"KP Locher","year":"2009","unstructured":"Locher KP (2009) Review. Structure and mechanism of ATP-binding cassette transporters. Philos Trans R Soc Lond B Biol Sci 364(1514):239\u2013245. https:\/\/doi.org\/10.1098\/rstb.2008.0125","journal-title":"Philos Trans R Soc Lond B Biol Sci"}],"container-title":["Neurogenetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10048-026-00881-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10048-026-00881-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10048-026-00881-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T21:01:47Z","timestamp":1773522107000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10048-026-00881-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,14]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["881"],"URL":"https:\/\/doi.org\/10.1007\/s10048-026-00881-8","relation":{},"ISSN":["1364-6753"],"issn-type":[{"value":"1364-6753","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,14]]},"assertion":[{"value":"5 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22"}}